Thursday, 5 July 2018

Hitting cancer early: AstraZeneca's bid to outmaneuver rivals

LONDON (Reuters) - AstraZeneca suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)